Drug · CHEMBL13

METOPROLOL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. METOPROLOL. Drugs and targets, record CHEMBL13. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL13

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: METOPROLOL; ChEMBL
ChEMBL ID: CHEMBL13; ChEMBL
Type: Small molecule; ChEMBL
Other names: (rs)-metoprolol, Beatrolol, CGP-2175, Dl-metoprolol, H-93/26, Lopressidone, Metoprolol slow release, Seroken; ChEMBL
Other form: METOPROLOL FUMARATE, CHEMBL3989566; Drugs and targets
Other form: METOPROLOL SUCCINATE, CHEMBL2356097; Drugs and targets
Other form: METOPROLOL TARTRATE, CHEMBL2062335; Drugs and targets
DrugBank: DB00264; DrugBank
InChIKey: IUBSYMUCCVWXPE-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 53 diseases, from ATC and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ADRB1	Beta-1 adrenergic receptor	Beta-1 adrenergic receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/153

Source ChEMBL

Diseases53

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Approval	TTD	27	26	https://conductscience.org/library/drugs?q=MONDO_0005044
heart failure	Phase 3	ClinicalTrials.gov	13	13	https://conductscience.org/library/drugs?q=MONDO_0005252
atrial fibrillation	Phase 3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0004981
myocardial infarction	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005068
coronary artery disorder	Unknown	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005010
essential hypertension	Phase 2/3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0001134
type 2 diabetes mellitus	Phase 2/3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005148
Tachycardia	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0001649
acute coronary syndrome	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005542
angina pectoris	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0003913

1 to 10 of 53Source Open Targets

See all 53 diseases

Trials161

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 81 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01203852	Pharmacogenomic Evaluation of Antihypertensive Responses 2	Phase 4	839	2015-05-19	metoprolol	Its name	ClinicalTrials.gov
NCT02336607	The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.		529	2015-03-23	metoprolol	Its name	ClinicalTrials.gov
NCT00142584	Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension	Phase 3	336	2022-03-15	metoprolol	Its name	ClinicalTrials.gov
NCT00953212	Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery	Phase 3	304	2018-03-29	beta blockers	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT01213173	Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients	Phase 4	251	2013-08-26	metoprolol	Its name	ClinicalTrials.gov
NCT00744237	Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients	Phase 4	231	2011-07-29	metoprolol	Its name	ClinicalTrials.gov
NCT01837069	Risk Factor Control Before Orthopedic Surgery	Phase 4	198	2020-07-27	metoprolol	Its name	ClinicalTrials.gov
NCT01049009	The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension	Phase 4	91	2014-12-19	metoprolol	Its name	ClinicalTrials.gov
NCT02484859	Comparison of Metoprolol and Tramadol With Remifentanil in Endoscopic Sinus Surgery	Phase 4	88	2019-09-10	metoprolol	Its name	ClinicalTrials.gov
NCT03070184	Race, Natriuretic Peptides and Physiological Perturbations	Phase 2	80	2025-02-27	metoprolol	Its name	ClinicalTrials.gov

1 to 10 of 161

See all 161 trials

Comparisons in its trials42

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
1-NEB vs 2-MET: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	150 of 252	51 of 84	336	NCT00142584	Trial comparisons
1-NEB vs 2-MET: deaths from any cause	3 of 252	0 of 84	336	NCT00142584	Trial comparisons
1-NEB vs 2-MET: serious adverse events	11 of 252	2 of 84	336	NCT00142584	Trial comparisons
Active Comparator vs Experimental: serious adverse events	1 of 139	3 of 112	251	NCT01213173	Trial comparisons
Arm 1 - Active Comparator vs Arm 2 - Experimental: The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups	25 of 116	28 of 115	231	NCT01213173	Trial comparisons
Arm 1 - Active Comparator vs Arm 2 - Experimental: The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups	28 of 116	46 of 115	231	NCT01213173	Trial comparisons
Treatment vs Control: Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism	10 of 103	2 of 95	198	NCT01837069	Trial comparisons
Treatment vs Control: deaths from any cause	0 of 103	0 of 95	198	NCT01837069	Trial comparisons
Treatment vs Control: serious adverse events	0 of 103	0 of 95	198	NCT01837069	Trial comparisons
Remifentanil vs Tramadol + Metoprolol: Number of Participants With Postoperative Nausea and Vomiting	14 of 44	10 of 44	88	NCT02484859	Trial comparisons

1 to 10 of 42

See all 42 comparisons in its trials

Papers from its trials95

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39948072	RESULT	1	PubMed
38109984	RESULT	1	PubMed
37622654	RESULT	1	PubMed
27050189	RESULT	1	PubMed
26285691	RESULT	1	PubMed
24694530	RESULT	1	PubMed
23580745	RESULT	1	PubMed
22353614	RESULT	1	PubMed
21558357	RESULT	1	PubMed
20818902	RESULT	1	PubMed

1 to 10 of 95

See all 95 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL13

GET https://conductscience.org/api/drugs/v1/CHEMBL13/diseases?page=2

API reference For AI assistants